DeFi Dev Corp. Grows SOL Treasury to 999,999, Raises $19 Million from Equity Line of Credit
This milestone follows the Company's most recent purchase of 141,383 SOL between July 14 - July 20, at an average purchase price of $133.53, representing a total value of approximately $19 million. The purchased SOL includes both spot purchases and discounted locked SOL. The Company's total SOL position includes rewards generated through staking and onchain activities.
Below is a summary of DeFi Dev Corp.'s current SOL position and key per-share metrics as of July 20, 2025:
Total SOL & SOL Equivalents Held: 999,999, representing a 142,250 increase vs. our previous balance of 857,749
Total SOL & SOL Equivalents Held (USD): approximately $181 million
Organic SOL Growth: Approximately 867 SOL was earned via staking, validator revenue, and other onchain activity between July 14 - July 20
Total Shares Outstanding as of July 18, 2025: 19,445,837
SOL per Share ('SPS'): 0.0514, representing an approximate 13% increase week over week
SPS (USD): $9.30
The newly acquired SOL will be held long-term and staked to a variety of validators, including DeFi Dev Corp.'s own Solana validators to generate native yield.
Equity Line of Credit Usage
Month-to-date, DeFi Dev Corp. raised approximately $19.2 million in net proceeds through its Equity Line of Credit facility ('ELOC'), issuing 740,000 shares of common stock. Approximately $5 million of the proceeds remains available primarily for future SOL purchases.
To date, DeFi Dev Corp. has drawn 0.4% of the total available capacity under its ELOC. Approximately $4.98B remains available under the facility.
Staking Update
As of July 20, 2025, substantially all of the Company's unlocked SOL was staked to its own validator infrastructure, generating native yield through staking. In addition to staking its own SOL, the Company's validators also receive third-party delegated stake from outside participants, creating an additional stream of revenue. Between July 14 - July 20, the Company earned approximately 867 SOL in staking, validator, and onchain rewards.
The Company will continue to provide suitable updates to our Treasury and underlying strategies, through public releases and regulatory filing(s), as available.
About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance ('DeFi') opportunities and continues to explore innovative ways to support and benefit from Solana's expanding application layer.
The Company is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions, as well as value-add services, to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage.
The Company currently serves more than one million web users annually, including multifamily and commercial property owners and developers applying for billions of dollars of debt financing per year, professional service providers, and thousands of multifamily and commercial property lenders, including more than 10% of the banks in America, credit unions, real estate investment trusts ('REITs'), debt funds, Fannie Mae® and Freddie Mac® multifamily lenders, FHA multifamily lenders, commercial mortgage-backed securities ('CMBS') lenders, Small Business Administration ('SBA') lenders, and more. The Company's data and software offerings are generally offered on a subscription basis as software as a service ('SaaS').
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," strategy," "future," "likely," "may,", "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated impairment charges that the Company may incur as a result of a decrease in the market price of SOL below the value at which the Company's SOL are carried on its balance sheet; (ii) the effect of and uncertainties related to the ongoing volatility in interest rates; (iii) our ability to achieve and maintain profitability in the future; (iv) the impact on our business of the regulatory environment and complexities with compliance related to such environment including changes in securities laws or other laws or regulations; (v) changes in the accounting treatment relating to the Company's SOL holdings; (vi) our ability to respond to general economic conditions; (vii) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (viii) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth and (ix) other risks and uncertainties more fully in the section captioned "Risk Factors" in the Company's most recent Annual Report on Form 10-K and other reports we file with the SEC. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
2 Dividend ETFs to Buy With $1,000 and Hold Forever
Key Points The Schwab U.S. Dividend Equity ETF provides exposure to high-quality, dividend-paying U.S. companies. The Vanguard Dividend Appreciation ETF is a popular choice for exposure to companies with a history of increasing their dividends in any economy. 10 stocks we like better than Schwab U.S. Dividend Equity ETF › Dividends can be a great way to boost your overall portfolio returns and generate capital to save, reinvest, or otherwise put to work as you desire. You can choose shares of individual income stocks or use dividend exchange-traded funds (ETFs) that provide access to an entire basket of dividend stocks. If you're considering dividend ETFs for your portfolio right now and have $1,000 to put to work, here are two options to consider. 1. Schwab U.S. Dividend Equity ETF The Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) tracks the performance of the Dow Jones U.S. Dividend 100 index, which tracks the performance of 100 high-yield U.S. dividend stocks. As such, the ETF typically invests in about 100 stocks across various sectors like energy, consumer staples, healthcare, technology, and industrials. Some of the top holdings of this fund include Chevron, ConocoPhillips, PepsiCo, Amgen, Cisco, Merck, and AbbVie. It also has positions in Target, General Mills, Paychex, and Lockheed Martin. The Schwab U.S. Dividend Equity ETF is built around companies that have paid dividends for at least 10 consecutive years and possess the financial strength to continue doing so. That underlying emphasis on quality and strong fundamentals helps create a more resilient and potentially stable portfolio that has paid off big for investors through the years. The ETF contained about $69 billion in total assets at the time of this writing, with an expense ratio of 0.06%. Considering that the average expense ratio for ETFs is in the ballpark of 0.1%, an expense ratio of 0.06% falls nicely below this average. It's worth noting that the Schwab U.S. Dividend Equity ETF is passively managed since it aims to replicate the performance of its chosen index rather than having a manager actively selecting and trading stocks. In general, passively managed ETFs tend to have lower expense ratios compared to actively managed funds because they don't require the same level of research and trading activity. The ETF also offers a yield of about 3.85%, notably higher than the average S&P 500 stock (1.3%). With a total 10-year return including dividends of about 200%, and its payout spiking by 160% in that time frame, the Schwab U.S. Dividend Equity ETF looks like a no-brainer buy for income-seeking investors who want to put cash into a basket of high-quality companies and hold it forever. 2. Vanguard Dividend Appreciation ETF The Vanguard Dividend Appreciation ETF (NYSEMKT: VIG) tracks the performance of the S&P U.S. Dividend Growers index, which replicates the performance of large U.S. companies that have consistently increased their dividends for at least 10 consecutive years. The top industry weightings in the Vanguard Dividend Appreciation ETF include technology, financial services, healthcare, consumer defensive, and industrials. The fund had total net assets of $109.6 billion at the time of this writing and contains 337 stocks with a median market cap of $226 billion. Most of the stocks in the ETF are large-cap companies (78% to be exact), while only about 2.7% are small caps. Some of the major names that represent the most significant holdings in the ETF include Microsoft, Apple, Eli Lilly, and Visa. Its current yield is relatively low compared to some other dividend ETFs (around 1.65%) because it prioritizes dividend growth over initial high payouts or the highest yields. Many of the underlying companies are growth-focused stocks that offer the potential for consistent capital appreciation alongside dividend income. Its current expense ratio of 0.05% is on the low end, making it accessible to a much wider group of investors. The Vanguard Dividend Appreciation ETF has delivered a total return of about 240% over the trailing 10 years, while its dividend has increased by about 97%. For investors seeking long-term, reliable income through exposure to high-quality, large-cap U.S. companies with a demonstrated track record of increasing their dividends, this ETF could warrant a long-term portfolio position. Should you invest $1,000 in Schwab U.S. Dividend Equity ETF right now? Before you buy stock in Schwab U.S. Dividend Equity ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Schwab U.S. Dividend Equity ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
24 minutes ago
- Globe and Mail
With the Red Hot IPO Market Raging, Will This Crypto Exchange Backed by Peter Thiel and Cathie Wood Be Wall Street's Next Moon Shot?
Key Points Figma's IPO last week showed that there is high demand from Wall Street. Now, a crypto exchange called Bullish is planning to go public at a valuation as high as $4.2 billion. The exchange is backed by Peter Thiel, and Cathie Wood has already committed to purchasing a block of shares. 10 stocks we like better than Figma › If you didn't believe it after CoreWeave and Circle, then Figma's monster $1.2 billion debut on the public markets made it official: Initial public offerings (IPOs) are back, and in a big way. After several years of a moribund IPO market, conditions have started to thaw, and there seems to be more demand from Wall Street. Shortly after Figma, a crypto exchange called Bullish, backed by the tech billionaire Peter Thiel, announced it would go public. The shares could start trading as soon as this week. "We now intend to IPO because we believe that the digital assets industry is beginning its next leg of growth," Bullish's Chief Executive Officer Tom Farley said in the offering's registration statement with the Securities and Exchange Commission. Trying to capitalize on crypto and stablecoins Bullish wants to raise just over $629 million in an IPO that would value the company at more than $4.2 billion. Interestingly, Bullish is planning to convert a chunk of the proceeds into a U.S. dollar-backed stablecoin. The crypto exchange focuses on institutional traders, offering a variety of services including spot, margin, derivatives trading, and liquidity and risk management. Bullish also provides a subscription-based liquidity and stablecoin service for various assets. Bullish had handled more than $1.25 trillion of volume at the end of the first quarter. Bullish is regulated in Germany, Hong Kong, and Gibraltar, and is pursuing licenses in other countries, including the U.S. Bullish also acquired the popular crypto news website and data provider CoinDesk to offer investors insights, proprietary industry benchmarks and indexes, and news insights, although in terms of revenue, CoinDesk makes up a small percentage of the overall company. Bullish is a fairly difficult company to analyze, primarily because its results seem so heavily affected by changing crypto prices. For instance, between 2022 and 2024, net income came in at a $4.2 billion loss, a $1.3 billion profit, and a nearly $80 million profit, respectively. That's largely because these numbers include the change in the fair value of digital assets it held. Bullish does attempt to strip out some of the volatility by providing adjusted revenue, net income, and earnings before interest, taxes, depreciation, and amortization (EBITDA). Among other exclusions, adjusted EBITDA leaves out digital asset sales and the cost of digital assets derecognized; gains or losses from the remeasurement of the company's digital assets; certain non-cash expenses like stock-based compensation; and the change in the fair value of investments in financial assets related to digital asset funds. Here is the company's adjusted revenue, EBITDA, and net income in the years from 2022 to 2024. Operating Metric (millions) 2022 2023 2024 Adjusted Revenue 191 150 214 Adjusted EBITDA 36 27 52 Adjusted Net Income 29 22 10 Source: Bullish registration statement Looking purely at trading volume on the platform, growth has been strong, climbing from roughly $145 billion in 2022 to $546 billion in 2024. In the 2025 first quarter, trading volume came in at an annualized pace of $918 billion. The company says its growth strategy will include obtaining more regulatory licenses, new product development, building its customer base, and mergers and acquisitions. Can Bullish be the next IPO moonshot? There are certainly some things working in Bullish's favor. For one, regulatory clarity has provided a tailwind for crypto companies, with more people in mainstream finance willing to get involved. Bullish noted that Ark Invest's Cathie Wood and BlackRock have already agreed to purchase $200 million worth of shares. It also looks like the company could debut with a low public float, limiting how many shares are available for trading. It's only offering 20.3 million shares in the IPO, and the company's registration statement lists a diluted weighted average share count of more than 226 million at the end of the first quarter. The growth in trading volume is also impressive. Given the demand for IPOs, particularly in crypto, the notable names behind this one, and the low number of shares being offered, I could see a pop out of the gate. However, looking at the adjusted numbers, the valuation seems lofty, so I could see any pop being followed by a sell-off as investors quickly take profits. The Bullish IPO could be volatile, and I'm staying on the sidelines. Should you invest $1,000 in Figma right now? Before you buy stock in Figma, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Figma wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
an hour ago
- Globe and Mail
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
